Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV

By sjmartinez • April 9, 2025

Daar ES, Orkin C, Sax PE, Hagins D, Pozniak A, Workowski K, Brinson C, Tiraboschi JM, Liu H, Deaton C, Cohen C, Madera S, Hindman JT, Ramgopal M. Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV. AIDS Res Ther. 2025 Apr 7;22(1):45. doi: 10.1186/s12981-025-00732-w. PMID: 40197415; PMCID: PMC11978100.

Tags: antiretroviral therapy, Bictegravir, body mass index, dolutegravir, glucose, Harbor UCLA, HIV-1, Infectious Diseases, Publications, Tenofovir alafenamide

Coronary Inflammation Is Associated With Plaque Progression in Men With HIV

Nasrallah N, Atallah M, Lattouf C, Harb T, Gerstenblith G, Haberlen S, Kelesidis T, Magnani JW, Stosor V, Chan K, Shirodaria C, Brown TT, Hays[...]

Metastatic Cutaneous Apocrine Carcinoma: Diagnostic and Therapeutic Challenges in a Rare Malignancy

Chan BL, Iguh C, Hwang A, Huang C. Metastatic Cutaneous Apocrine Carcinoma: Diagnostic and Therapeutic Challenges in a Rare Malignancy. Cureus. 2026 Jul 21;18(7):e113113. doi:[...]

The future of home oxygen therapy

Holland AE, Krishnan JA, Lacasse Y, Gomes H, Björklund F, Casaburi R, de Andrade J, Eakin MN, Hui D, Jacobs SS, Kawachi S, Khor YH,[...]